- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 26th, 2007
It's no secret that certain nanotechnology stocks get whipsawed as news and investor enthusiasm for this new science heats up and then cools. Publicly traded nanotechnology venture capital firm Harris & Harris Group (nasdaq: TINY - news - people ) is a case in point.
This New York City-based firm is invested in a diversified range of early-stage nanotech companies. Its portfolio consists of 27 private companies, and its shares trade mostly on investor hype over their potential for growth. Earlier this month, the stock hovered around $11.50, with a market cap of $245.2 million. But with net assets of $113,930,303 and 21,015,017 shares outstanding at the end of 2006, TINY's net asset value (NAV) per outstanding share was $5.42. That means investors were getting $5.42 worth of value for a share price of $11.50--not a great trade if you're measuring performance by the usual metrics of sales and profits.
But, as I've written in earlier issues, conventional valuation metrics do not apply well to business development companies (BDCs) like Harris & Harris or similar firms, such as Allied Capital (nyse: ALD - news - people ) or MCG Capital (nasdaq: MCGC - news - people ). Since the growth of BDCs is so closely linked to the potential appreciation of their portfolios, most investors pay closer attention to the NAV--or more specifically, to how the share price compares with the NAV. Even by that measure, however, TINY's stock would seem overvalued.
|Related News Press|
Nanometrics Announces Upcoming Investor Events July 20th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Attosecond physics: Mapping electromagnetic waveforms July 25th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016